Cantor Fitzgerald Reiterates Overweight Rating and $12 PT on Lucid Diagnostics (LUCD), "We Encourage Investors to Acquire LUCD Shares at Attractive Valuation"
Tweet Send to a Friend
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $12.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
